TrialSignal
Clinical trial intelligence report
A Bioequivalence Study of Fixed-dose Combination Tablet of 5 Milligrams Saxagliptin/10 Milligrams Dapagliflozin Relative to Their Respective Individual Components Coadministered to Healthy Subjects in the Fasted State
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT02223065-Jul 28, 2026
NCT ID
NCT02223065
Status
COMPLETED
Phase
PHASE1
Sponsor
AstraZeneca
Executive brief
Investment-Ready Snapshot
A Bioequivalence Study of Fixed-dose Combination Tablet of 5 Milligrams Saxagliptin/10 Milligrams Dapagliflozin Relative to Their Respective Individual Components Coadministered to Healthy Subjects in the Fasted State is a PHASE1 clinical asset sponsored by AstraZeneca in Type 2 Diabetes Mellitus. SEO and diligence focus: Saxagliptin, Dapagliflozin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02223065
Indication
Type 2 Diabetes Mellitus
Modality
small molecule
Target
Saxagliptin, Dapagliflozin
Intervention
Saxagliptin, Dapagliflozin
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.